SEPARATION, TRANSITION AND GENERAL RELEASE AGREEMENTSeparation, Transition and General Release Agreement • December 10th, 2020 • 8x8 Inc /De/ • Services-computer processing & data preparation • California
Contract Type FiledDecember 10th, 2020 Company Industry JurisdictionThis Separation, Transition and General Release Agreement (“Separation Agreement”) is entered into between Vikram Verma (referred to as “Employee” or “you”), and 8x8, Inc. (referred to as “8x8” or the “Company”), regarding Employee’s separation of employment with 8x8. Together Employee and the Company are referred to as the “Parties” or individually as a “Party.”
SEPARATION, TRANSITION AND GENERAL RELEASE AGREEMENTSeparation, Transition and General Release Agreement • March 9th, 2018 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Maryland
Contract Type FiledMarch 9th, 2018 Company Industry JurisdictionThis Separation, Transition and General Release Agreement is entered between Rexahn Pharmaceuticals, Inc. (the “Company”) and Tae Heum (Ted) Jeong (hereinafter Dr. Jeong) this 11th day of December, 2017 and shall be effective as of the Effective Date (as set forth in Section 7).
CONFIDENTIAL SEPARATION, TRANSITION AND GENERAL RELEASE AGREEMENTSeparation, Transition and General Release Agreement • June 8th, 2023 • Phunware, Inc. • Services-computer processing & data preparation • Texas
Contract Type FiledJune 8th, 2023 Company Industry JurisdictionThis CONFIDENTIAL SEPARATION, TRANSITION AND GENERAL RELEASE AGREEMENT, dated as of June 2, 2023 (this "Agreement"), by and between Phunware, Inc., a Delaware corporation (the "Company") and Matt Aune ("Executive"). The Company and Executive are sometimes referred to herein collectively as the "Parties" and individually as a "Party."
SEPARATION, TRANSITION AND GENERAL RELEASE AGREEMENTSeparation, Transition and General Release Agreement • November 16th, 2018 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations • Maryland
Contract Type FiledNovember 16th, 2018 Company Industry JurisdictionThis Separation, Transition and General Release Agreement is entered between Rexahn Pharmaceuticals, Inc. (the “Company”) and Peter Suzdak, Ph.D. (“Executive”) this 14th day of November 2018 and shall be effective as of the Effective Date (as set forth in Section 7).